Study guide
13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
Key Takeaways Explain This Topic AI
NICE NG12 refers women aged 30 or over with an unexplained breast lump on the suspected cancer pathway, and people aged 50 or over with unilateral nipple discharge, retraction or other concerning nipple change.
Breast lumps are assessed by triple assessment: clinical examination, imaging (ultrasound under 40, mammography plus ultrasound from 40) and core biopsy.
The NHS Breast Screening Programme invites women aged 50 to their 71st birthday for mammography every 3 years.
Tamoxifen increases the risk of VTE and endometrial cancer, whereas aromatase inhibitors cause bone loss and need bone density monitoring.
Lactational mastitis is managed by continuing to breastfeed or express, with flucloxacillin if infection is likely; a breast abscess needs ultrasound-guided drainage.
Last updated: October 2026
- Breast Disease, Cancer Screening & Suspected Cancer Referral
- Assessing a Breast Symptom
- NICE NG12 Referral Criteria
Suspected cancer pathway referral:
- aged 30 or over with an unexplained breast lump (with or without pain)
- aged 50 or over with discharge, retraction or other concerning change of one nipple only
Consider a suspected cancer pathway referral: skin changes suggestive of breast cancer (peau d'orange, tethering, ulceration), or aged 30 or over with an unexplained axillary lump .
Consider a non-urgent referral: under 30 with an unexplained breast lump.
Triple Assessment (in the breast clinic)
Clinical history and examination (both breasts and axillae).
Imaging: ultrasound under 40 (dense breast tissue); mammography plus ultrasound from 40 .
Tissue sampling: core needle biopsy (or fine-needle aspiration of cysts and axillary nodes).
Benign Breast Conditions
Condition Typical Patient Features Management
Fibroadenoma Under 30 Smooth, firm, highly mobile ("breast mouse"), painless Reassure after triple assessment; excise if large or growing
Breast cyst 35–55, perimenopausal Smooth, fluctuant, may be tender Ultrasound and aspiration; investigate if blood-stained or recurs
Fibrocystic change Premenopausal Cyclical lumpiness and pain Supportive bra, analgesia
Lactational mastitis Breastfeeding Painful, red, wedge-shaped area, fever Continue breastfeeding or expressing ; flucloxacillin if infection is likely (erythromycin or clarithromycin if allergic)
Breast abscess Lactating or smokers (non-lactational) Fluctuant, tender mass, systemic upset Ultrasound-guided aspiration or drainage plus antibiotics
Duct ectasia Perimenopausal, smokers Thick, coloured nipple discharge, nipple retraction Exclude cancer; reassure
- Intraductal papilloma 35–55 Blood-stained discharge from a single duct Imaging and excision
- Fat necrosis After trauma or surgery Firm, irregular lump that can mimic cancer Triple assessment
Gynaecomastia Males (puberty, older men) Rubbery subareolar tissue Review drugs ( spironolactone , digoxin, anti-androgens, cannabis), liver disease, hypogonadism and testicular tumours (hCG) ; men 50 or over with a unilateral firm subareolar mass need a suspected cancer referral
Breast Cancer
The most common cancer in UK women (about 1 in 7 lifetime risk).
Risk factors: age, BRCA1/BRCA2 and other inherited variants, strong family history, previous breast cancer or atypical hyperplasia, early menarche, late menopause, nulliparity or late first pregnancy, combined HRT, alcohol, obesity after menopause and chest radiotherapy.
Family history (NICE CG164): refer to a family history or genetics service if criteria are met (for example several affected relatives, young age at diagnosis, male breast cancer, or ovarian cancer in the family); higher-risk women receive earlier or enhanced surveillance (including annual MRI for BRCA carriers in their 30s and 40s) and may consider risk-reducing medication or surgery.
Presentation: a painless hard irregular lump, skin tethering, peau d'orange , nipple retraction or eczema-like change ( Paget's disease of the nipple ), axillary nodes.
Treatment principles:
Surgery: wide local excision with radiotherapy, or mastectomy; sentinel lymph node biopsy to stage the axilla.
Hormone therapy for oestrogen receptor-positive tumours: tamoxifen (mainly premenopausal; risks VTE , endometrial cancer and hot flushes) or an aromatase inhibitor such as letrozole or anastrozole (postmenopausal; causes bone loss , so check bone density and consider bisphosphonates).
HER2-targeted therapy (trastuzumab) for HER2-positive tumours; it can cause cardiotoxicity , so cardiac function is monitored.
Chemotherapy according to risk.
UK Cancer Screening Programmes
- Programme Who Test & Interval
- Breast Women aged 50 to 71st birthday (older women can self-refer) Mammography every 3 years
- Cervical People with a cervix aged 25–64 HPV testing , every 5 years if HPV-negative (section 9.3)
- Bowel (England) Aged 50–74 Home FIT every 2 years ; colonoscopy if abnormal
- Lung Aged about 55–74 with a smoking history Risk assessment and low-dose CT (being rolled out nationally)
- AAA Men in the year they turn 65 One-off abdominal ultrasound (section 2.6)
Screening tests aim to find disease before symptoms. Symptomatic patients should never be told to wait for screening ; they need diagnostic assessment. There is no national prostate or ovarian screening programme ; PSA and CA125 are used for symptomatic assessment, not population screening.
Suspected Cancer Referral Principles
The suspected cancer pathway (formerly the "2-week wait") aims for a diagnosis or ruling out of cancer within 28 days (the Faster Diagnosis Standard).
Non-specific symptoms pathways (rapid diagnostic centres) accept patients with vague but concerning features such as unexplained weight loss, fatigue or abdominal pain.
Safety-netting: explain the referral and why it matters, give clear advice about when to return, and check that appointments and results are followed up; record discussions in the notes.
Tumour markers (CA125, PSA, AFP, CEA) have specific roles in symptomatic assessment or monitoring but are not general screening tests.
Breaking bad news uses a structured approach (such as SPIKES): set up a private setting, explore what the patient knows and wants to know, give a warning shot, deliver information clearly without jargon, respond to emotions, and agree a plan with follow-up.
Loading diagram...